Pharma's Market
- Friday, 20 Nov 2009 2:51 PM ETBy: Mike Huckman
Investors, patients and activists, no doubt, hope they won't have to put out a mayday distress call, but as Dendrama's fate would have it, the company announced today that the Food and Drug Administration has assigned May Day as its decision day for the prostate cancer treatment Provenge. » Read more - Friday, 20 Nov 2009 12:04 PM ETBy: Mike HuckmanEarlier this week I reported that Dr. Allen Taylor who ran the Abbott vs. Merck cholesterol drug study, which Abbott's drug Niaspan won, would only say that ABT has paid him more than $10,000 in lecture and consulting fees. But he wouldn't be any more specific than that. » Read more
- Wednesday, 18 Nov 2009 12:03 PM ETBy: Mike HuckmanVVUS this morning unveiled positive late-stage test results on the ED pill. The company touts that it takes effect in less than 30 minutes and it's out of your system within six hours or so. » Read more
- Tuesday, 17 Nov 2009 4:09 PM ETBy: Mike HuckmanWhen I do an interview with a clinical trial investigator I typically try to take care of what I call the "housekeeping" at the beginning or end. » Read more
- Monday, 16 Nov 2009 3:09 PM ETBy: Mike HuckmanLive TV is best when things are happening and news is breaking right now. It's immediate and often, hopefully, more compelling. » Read more
- Friday, 13 Nov 2009 11:55 AM ETBy: Mike Huckman
It doesn't always happen, but there is a common to-and-fro, push-and-pull, back-and-forth or whatever you want to call it between reporters and corporate PR folks. I don't particularly like that part of my job, but sometimes it just comes with the territory. I've got my job to do and they've got theirs. I get it. » Read more - Thursday, 12 Nov 2009 11:32 AM ETBy: Mike Huckman
Today starts a two-day FDA public hearing in Washington, DC on biopharma and social media. I decided not to go because talking heads in a meeting room just don't make for good TV. And this is just the first step in what is no doubt going to be a very long, involved policy-making process. But as it turns out, it looks like it might have been futile for me to try to attend anyway. » Read more - Tuesday, 10 Nov 2009 2:46 PM ETBy: Mike Huckman
When I went to the FDA's Web site today I was surprised to see on the homepage a link to a letter written by Commissioner Dr. Peggy Hamburg. It's addressed to "Dear Healthcare Professional" aka a "Dear Doctor letter." That's a common type of communication from the agency and/or companies to the medical community, usually when they've got bad news to pass along about a drug or device. It's pretty rare for the commish to write one. » Read more
ABOUT PHARMA'S MARKET
Pharma's Market is more than just a play on words. Think of this blog written by Mike Huckman as a “farmer's market”—a place where you'll find a wide assortment of fresh stuff related to the drug, biotech and medical device industries. Mike will try to harvest topics from fertile, untilled ground. And yes, occasionally, he'll go off the farm.
BIO
Mike Huckman is the author of CNBC.com’s Pharma’s Market and CNBC's Pharmaceuticals Reporter covering the drug, biotechnology and medical device industries. Huckman joined the network in 2000 and is based at the network’s global headquarters in Englewood Cliffs, N.J. Read full bio here.
MIKE HUCKMAN'S FAVORITE LINKS
PHARMA'S MARKET VIDEO
» More
Cholesterol Drug Battle: Niaspan vs. Zetia 
16 Nov 2009
Cardiologist Grades Cholesterol Drug Study 16 Nov 2009
Merck's Cholesterol Drugs Under Pressure 16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs 16 Nov 2009
Cholesterol Drug Battle 16 Nov 2009
Novo Nordisk CEO on Diabetes Epidemic 13 Nov 2009
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- HP Comes in As Expected; Is It Time to Buy?
- Prepare For Large Decline In Stocks, Next Year?
- Hewlett-Packard Profit Rises, Matches Guidance
- Wave of Debt Payments Facing US Government
- Nov. 23: Unusual Volume Leaders
- Paul: Audit the Fed
- The Social Media Gaming Threat
- Holiday Travel Outlook
- Lyondell Urged to Consider Reliance Takeover Offer
- Lightning Round: AT&T, Verizon, Novartis and More
- Lightning Round OT: Alcoa, Weight Watchers and More
- Why Amazon Rules Retail
- Nordic American: Sinking Ship or Titan Tanker?
- Your First Move For Tuesday November 24th
- Cramer: What Monday’s Housing Number Really Means
- Pops & Drops: Cigna, Verizon...
- Giving Thanks: Energy
- Web Extra: Winning The Chocolate Wars
- Holiday Travel Outlook
RSS FEED
» Help
powered by digg
About CNBC | Site Map | Privacy Policy | Terms of Service | Video Reprints | Advertise | Help | Contact
Partners: AOL Money | BloggingStocks.com
Partners: AOL Money | BloggingStocks.com
Data is a real-time snapshot *Data is delayed at least 15 minutesGlobal Business and Financial News, Stock Quotes, and Market Data and Analysis
© 2009 CNBC, Inc. All Rights Reserved.
A Division of NBC Universal
